RxDoctor Payments Data

Brittany York

Family · Laurinburg, NCNPI 1548927841

Payments from drug & device makers

$623in general payments, 2019–2025

Across 25 payments — averaging $24.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$322
  • Corcept Therapeutics$110
  • ANI Pharmaceuticals, Inc.$44
  • Grifols USA, LLC$43
  • Abbott$24
  • Trisalus Life Sciences, Inc.$22
  • plus $59 from 4 others

What the payments were for

  • Food & beverage$623100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$623 in reported general payments places this provider in the 60th percentile of 4,522 family providers in North Carolina.

See all family providers in North Carolina

Medicare billing

Part B allowed, 2024
$848
Medicare patients
21
Services billed
93

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide69$107,743
JardianceEmpagliflozin73$71,172
FarxigaDapagliflozin Propanediol39$50,826
LinzessLinaclotide51$47,520
JanuviaSitagliptin Phosphate39$46,301
TrulicityDulaglutide29$37,745
EliquisApixaban39$34,200
Trelegy ElliptaFluticasone/Umeclidin/Vilanter35$24,123
MounjaroTirzepatide11$16,548
JanumetSitagliptin Phos/Metformin Hcl17$13,128
TradjentaLinagliptin15$11,509
SymbicortBudesonide/Formoterol Fumarate19$6,379
Spiriva RespimatTiotropium Bromide11$5,839
Albuterol Sulfate HfaAlbuterol Sulfate160$4,778
Lantus SolostarInsulin Glargine,hum.Rec.Anlog32$3,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$322$107,74369 claims
AstraZenecaFarxiga, Symbicort$15$57,20458 claims
Lilly USA, LLCTrulicity, Mounjaro$13$54,29340 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 4,522 family providers in North Carolina.

Other family in Laurinburg

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →